Risto-cel (BEAM-101) BLA submission in sickle cell disease, as early as year-end 2026
Risto-cel (BEAM-101) BLA submission in sickle cell disease, as early as year-end 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Beam (Risto-cel (BEAM-101) for Sickle cell disease): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Beam Therapeutics Inc. BEAM
- Drug
- Risto-cel (BEAM-101)
- For
- Sickle cell disease
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- Q4 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Company guidance: 'submit a biologics license application (BLA) for risto-cel as early as year-end 2026' (timing could slip into early 2027).
- Checked
- Checked by a person when it was added
- Source: globenewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BEAM headlines on this site
Beam expects to report results from its Phase 1/2 study of Risto-cel (BEAM-101) for Sickle cell disease in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
More details
- Entry
- Updated BEACON Phase 1/2 data for risto-cel by year-end 2026 · Clinical trial results (readout / topline data)
- Drug
- Risto-cel (BEAM-101)
- For
- Sickle cell disease
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Company guidance: 'expects to report updated data for the BEACON trial by year-end 2026.' Dosing complete in all adult and adolescent patients.
- Checked
- Checked by a person when it was added
- Verify it
- Source: globenewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BEAM headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Beam expects to report results from its Phase 1/2 study of BEAM-301 for Glycogen storage disease type Ia (R83C) in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
More details
- Entry
- BEAM-301 initial clinical data in glycogen storage disease type Ia · Clinical trial results (readout / topline data)
- Drug
- BEAM-301
- For
- Glycogen storage disease type Ia (R83C)
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Company guides initial clinical data 'in 2026'; only H2 2026 remains, hence the H2 tag.
- Checked
- Checked by a person when it was added
- Verify it
- Source: globenewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- BEAM headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page